We are excited to announce that Eagle IP has been named as a finalist for the Life Sciences Patent Network (LSPN) Awards USA 2025 in the following categories:   

  1. Inspiring Woman of the Year: This nomination recognizes our President and Managing Director, Ms. Jennifer Che, for her outstanding leadership, innovation, and dedication to empowering others in the industry.  
  1. International Firm of the Year: This nomination recognizes the excellence and achievements of international firms, such as Eagle IP. 

We are truly honored to be shortlisted in two different categories for the LSPN Awards USA 2025!  This award recognizes "excellence, innovation, and leadership in life sciences IP" and tries to identify individuals and organizations that are "shaping the future of pharmaceutical and biotech patent protection." This recognition is a testament to the hard work and dedication of our entire team. A heartfelt THANK YOU to our clients for your trust and support, to our incredible team for their continued pursuit of excellence, and to our partners for their collaboration. 

You can see all the finalists here. 

Our Past Events

Dr. Jacqueline Lui, Ms. Pauli Wong, and Mr. Eddie Ho Named Patent Stars by ManagingIP

13 June 2025

Eagle IP Ranked Among Top Tier Firms in IAM Patent 1000

12 June 2025

Jennifer Che from Eagle IP to Attend BIO 2025 in Boston!

11 June 2025

Insights from HKSTP Market Discovery - BIO Connect

28 May 2025

HKMHDIA Medical Fair Forum

27 May 2025

Celebrating Innovation at the Asia Summit for Global Health

26 May 2025

Recommended Insights

Foreign companies transferring IP out of China: things to know

25 October 2018
Inventions made in China Most foreign companies with R&D sites in China are aware of the fact that inventors having inventions made in China have to obtain permission before they can file patent applications outside of China for these Chinese inventions. It doesn’t matter if the owner of the business is a foreign entity. Patent […]
Read more >

IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 2: Grace Period without Loss of Novelty

7 February 2024
Background As mentioned in our earlier article, the Implementation Regulations of the Chinese Patent Law (“Regulations”, similar to the CFR in the US) were approved in November, and the CNIPA finally made public the full text of the Regulations just before the arrival of the New Year. At the same time, the CNIPA also released […]
Read more >

How to Protect a Crystal Form (Polymorph) Patent in China

4 June 2025
Crystalline forms are critical to pharmaceutical patents, offering extended protection for improved stability, bioavailability, or manufacturability. However, securing such patents in China has grown increasingly difficult due to the China National Intellectual Property Administration (CNIPA)’s strict patentability criteria. Unlike the U.S. or Europe, where structural novelty or problem-solving utility may suffice, China demands quantifiable evidence of […]
Read more >

First Ever Successful Invalidation Challenge Due to Unauthorized Foreign Filing

8 March 2023
What does an invention “completed” in China mean? China and the US are similar in that both countries highly value national security, and thus have rules regulating the exportation of technology and information from within their borders. This includes new inventions that arise from within their respective borders. As such, both governments require inventors who […]
Read more >
Top crossarrow-right